{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:04:21Z","timestamp":1776870261609,"version":"3.51.2"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research (NIHR)"},{"name":"MDPI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Acetazolamide, a carbonic anhydrase inhibitor, is used to treat a variety of ailments. It has been highlighted for its potential to benefit people with bipolar disorders, for whom there are clear current unmet treatment needs. This scoping review sought to synthesise all available evidence related to the potential effects of acetazolamide on symptoms related to bipolar disorder, acceptability and tolerability, and intervention characteristics (e.g., dose and duration). Following publication of the review protocol, the Pubmed, Embase, and PsycInfo databases were searched (all dated to 31 August 2022). A systematic approach was undertaken to identify eligible articles and extract relevant data from these. Five studies were included, assessing a total of 50 patients treated with acetazolamide. Most patients were from two open-label trials, while the others were case reports. Approximately one third of patients were experiencing psychosis or mania before treatment initiation, and one third had refractory depression. Forty-four percent of patients were estimated to achieve a response (not seemingly affected by the baseline episode type, acetazolamide dose, or duration), while a further 22% appeared to experience minimal benefits from the intervention. Acetazolamide was generally reported to be tolerated well and acceptable for up to 2 years, although reporting for acceptability and tolerability was suboptimal. The reviewed evidence is extremely limited in size and methodology (e.g., no randomised studies, blinding, or standardised outcome assessment). We posit that the current findings are sufficiently encouraging to recommend substantive clinical trials, but we emphasise that at present, the evidence is exceedingly preliminary, and there remains evident uncertainty as to whether acetazolamide could be a viable treatment for bipolar disorders.<\/jats:p>","DOI":"10.3390\/brainsci13010140","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T04:02:04Z","timestamp":1673582524000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acetazolamide for Bipolar Disorders: A Scoping Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2984-1124","authenticated-orcid":false,"given":"Rebecca","family":"Strawbridge","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London SE5 8AF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nefize","family":"Yalin","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London SE5 8AF, UK"},{"name":"South London & Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-2831","authenticated-orcid":false,"given":"Stelios","family":"Orfanos","sequence":"additional","affiliation":[{"name":"South London & Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London SE5 8AF, UK"},{"name":"South London & Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","unstructured":"(2021, September 04). World Health Organization: The Global Burden of Disease: 2004 Update. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/43942."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1017\/S1461145713000278","article-title":"Clinical management and burden of bipolar disorder: Results from a multinational longitudinal study (WAVE-bd)","volume":"16","author":"Vieta","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Strawbridge, R., Alexander, L., Richardson, T., Young, A.H., and Cleare, A.J. (2022). Is there a \u2018bipolar iceberg\u2019 in UK primary care psychological therapy services?. Psychol. Med., 1\u201310.","DOI":"10.1017\/S0033291722002343"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S2215-0366(18)30253-0","article-title":"Areas of uncertainties and unmet needs in bipolar disorders: Clinical and research perspectives","volume":"5","author":"Bauer","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/acps.13471","article-title":"A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder","volume":"146","author":"Strawbridge","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","article-title":"Evidence-based guidelines for treating bipolar disorder: Revised second edition--recommendations from the British Association for Psychopharmacology","volume":"23","author":"Goodwin","year":"2009","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_9","unstructured":"Yalin, N., Strawbridge, R., Dawson, K., Fouani, A., and Young, A. (2022, August 25). Monotherapy Versus Combined Therapies for Acute Mania: A Systematic Review of Benefits and Harms. Available online: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=309749."},{"key":"ref_10","unstructured":"Jauhar, S., Tong, C., Strawbridge, R., Arnone, D., and Young, A. (2022, August 25). Efficacy of Therapeutic Interventions in Bipolar Depression: A Systematic Review and Network Meta-Analysis. Available online: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=227477."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2021.08.264","article-title":"Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Nestsiarovich","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_12","unstructured":"Farzam, K., and Abdullah, M. (2022). Acetazolamide. StatPearls, StatPearls Publishing."},{"key":"ref_13","unstructured":"(2022, November 01). Acetazolamide 250 mg Tablets\u2014Summary of Product Characteristics (SmPC)\u2014(emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/2785\/smpc#gref."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0165-1781(89)90208-4","article-title":"Acetazolamide and thiamine: An ancillary therapy for chronic mental illness","volume":"28","author":"Sacks","year":"1989","journal-title":"Psychiatry Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10401239409148987","article-title":"Acetazolamide in bipolar affective disorders","volume":"6","author":"Hayes","year":"1994","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Strawbridge, R., Orfanos, S., Yalin, N., and Young, A.H. (2022). Is acetazolamide a potential intervention for people with bipolar disorders? A scoping review protocol. medRxiv.","DOI":"10.1101\/2022.08.27.22279292"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_19","first-page":"425","article-title":"Antipsychotic and prophylactic effects of acetazolamide (Diamox) on atypical psychosis","volume":"38","author":"Inoue","year":"1984","journal-title":"Folia Psychiatr. Neurol. Jpn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000026539","article-title":"Acetazolamide in the treatment of acute mania","volume":"38","author":"Brandt","year":"1998","journal-title":"Neuropsychobiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4088\/JCP.v58n0607b","article-title":"Lamotrigine treatment of refractory bipolar disorder","volume":"58","author":"Fogelson","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"ref_22","first-page":"249","article-title":"Prophylactic effect of carbonic anhydrase inhibitors on periodic psychosis of childhood","volume":"9","author":"Fukuma","year":"1980","journal-title":"Jpn. J. Clin. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00023210-200216010-00004","article-title":"The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: A 20-year review of its use as an outcome measure","volume":"16","author":"Bech","year":"2002","journal-title":"CNS Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1461145709991246","article-title":"Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: A systematic review and meta-analysis","volume":"13","author":"Tamayo","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4088\/JCP.v68n0520","article-title":"A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder","volume":"68","author":"DelBello","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-5618.2006.00276.x","article-title":"Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials","volume":"8","author":"Kushner","year":"2006","journal-title":"Bipolar Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/appi.ajp.163.2.210","article-title":"Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone","volume":"163","author":"Nierenberg","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000557","DOI":"10.1136\/bmjresp-2020-000557","article-title":"Side effects of acetazolamide: A systematic review and meta-analysis assessing overall risk and dose dependence","volume":"7","author":"Schmickl","year":"2020","journal-title":"BMJ Open Respir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euroneuro.2019.11.006","article-title":"Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy","volume":"31","author":"Schoot","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.2014.897328","article-title":"Safety of carbonic anhydrase inhibitors","volume":"13","author":"Swenson","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2010.01.023","article-title":"Acetazolamide improves cerebral hemodynamics in CADASIL","volume":"292","author":"Huang","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"ref_33","first-page":"1153","article-title":"Treatment of Kleine-Levin Syndrome with Acetazolamide","volume":"10","author":"Kapson","year":"2014","journal-title":"J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Provensi, G., Carta, F., Nocentini, A., Supuran, C.T., Casamenti, F., Passani, M.B., and Fossati, S. (2019). A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194724"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0278-5846(94)90078-7","article-title":"The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania","volume":"18","author":"Kanba","year":"1994","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14656566.8.1.111","article-title":"Zonisamide for bipolar depression","volume":"8","author":"Wilson","year":"2007","journal-title":"EXPERT Opin. Pharmacother."},{"key":"ref_37","first-page":"297","article-title":"The adverse event profile of zonisamide: A meta-analysis","volume":"128","author":"Verrotti","year":"2013","journal-title":"ACTA Neurol. Scand."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100023","DOI":"10.1016\/j.metop.2020.100023","article-title":"Acetazolamide increases locomotion, exploratory behavior, and weight loss following social stress: A treatment for emotional eating?","volume":"5","author":"Woodman","year":"2020","journal-title":"Metab. Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00004714-199706000-00009","article-title":"A Treatment for Tardive Dyskinesia and Some Other Extrapyramidal Symptoms","volume":"17","author":"Cowen","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1681\/ASN.2015070796","article-title":"Acetazolamide Attenuates Lithium\u2013Induced Nephrogenic Diabetes Insipidus","volume":"27","author":"Sinke","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"F669","DOI":"10.1152\/ajprenal.00147.2017","article-title":"Lithium-induced NDI: Acetazolamide reduces polyuria but does not improve urine concentrating ability","volume":"313","author":"Doornebal","year":"2017","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_42","first-page":"17","article-title":"Use of acetazolamide in lithium-induced nephrogenic diabetes insipidus: A case report","volume":"2018","author":"Macau","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_43","first-page":"148","article-title":"Double blind study on the prophylactic effect of carbonic anhydrase inhibitors on the manic phase","volume":"5","author":"Kaneko","year":"1973","journal-title":"Annu. Rep. Pharm. Res."},{"key":"ref_44","first-page":"497","article-title":"Trial of the therapy of manic disease with a carbonic anhydrase inhibitor, acetazolamide","volume":"7","author":"Inui","year":"1978","journal-title":"Jpn. J. Clin. Psychiatry"},{"key":"ref_45","first-page":"205","article-title":"A case of atypical psychosis on which carbonic anhydrase inhibitor was effective","volume":"4","author":"Inoue","year":"1975","journal-title":"Jpn. J. Clin. Psychiatry"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/1\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:12Z","timestamp":1760119512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/1\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["brainsci13010140"],"URL":"https:\/\/doi.org\/10.3390\/brainsci13010140","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}